Funding
The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
ASAP, 2023(SUPPLEMENT) Using Single-cell Analyses to Understand Inherited and Acquired Genetic Variation in Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is a disorder that not only affects the function of the brain, but also the gut. Both of these are complex tissues composed of functionally diverse cell types...
-
Data-Driven Subtyping and Stratification Program, 2023Longitudinal Investigation of Statistical Subtype Analysis in Genetic Forms of Parkinson’s Disease
Study Rationale: People with Parkinson’s disease (PD) experience different symptoms and disease course, even individuals with the same genetic form of PD. Because we do not yet understand the range of...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Examining the Role of LRRK2 and Glucocerebrosidase Dysfunction in Exosome-mediated Release of the Lipid Biomarker Bis(monocylglycero)phosphate in Parkinson's Disease
Study Rationale: Mutations in LRRK2 and GBA1 (which encodes the enzyme glucocerebrosidase, or GCase) are among the most common genetic risk factors for Parkinson’s disease (PD). Individuals with these...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Characterization of a Novel Strategy to Target LRRK2 and Its Downstream Signaling Pathway
Study Rationale: Genetic mutations that activate LRRK2 are linked to familial Parkinson’s disease (PD). However, no clinically approved inhibitors for LRRK2 currently exist. In this study, we will...
-
ASAP, 2023(SUPPLEMENT) Examining How Genes and Gut Bacteria Cooperate to Cause Parkinson’s Disease
Study Rationale: Recent studies suggest that the alpha-synuclein protein that forms aggregates in Parkinson’s disease (PD) may originate in the gut and travel along nerves that go to the brain...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Investigating the Molecular Basis of Neurodegeneration in GBA-associated Parkinson's Disease
Study Rationale: Mutations in GBA1, the gene that encodes the enzyme glucocerebrosidase (GCase), are among the most common genetic risk factor for the development of Parkinson’s disease (PD). GCase...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.